Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer

Tyrosine kinase inhibitors (TKI) play a pivotal role in the treatment of non-small-cell lung cancer (NSCLC) with mutations in epidermal growth factor receptor (EGFR) and rearrangements in anaplastic lymphoma kinase (ALK). However, the influences of TKIs on the tumor immune microenvironment (TIM), es...

Full description

Bibliographic Details
Main Authors: Yisheng Fang, Yuanyuan Wang, Dongqiang Zeng, Shimeng Zhi, Tingting Shu, Na Huang, Siting Zheng, Jianhua Wu, Yantan Liu, Genjie Huang, Yichen Xue, Jianping Bin, Yulin Liao, Min Shi, Wangjun Liao
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1951019